## הודעה על החמרה (מידע בטיחות) בעלון לרופא (מעודכן 3102.50)

\_\_\_July 13, 2015 \_\_\_ תאריך שם תכשיר באנגלית ומספר הרישום

PROGRAF CAPSULES 0.5 mg, 1 mg, 5 mg

0.5 mg: 122 07 30215 00, 122 07 30215 11,

1 mg: 107 69 29158 00, 107 69 29158 11,

5 mg: 107 70 29159 00, 107 70 29159 11

Salomon, Levin & Elstein Ltd, POBox 3696, Petach-Tikva 49133 שם בעל הרישום

טופס זה מיועד לפרוט ההחמרות בלבד!

ההחמרות המבוקשות				
טקסט חדש	טקסט נוכחי	פרק בעלון		
		Indication		
		Contraindications		
		Posology, dosage & administration		
Herbal preparations containing St. John's wort (Hypericum perforatum) or other herbal preparations should be avoided when taking Prograf due to the risk of interactions that lead to either a decrease in blood concentrations of tacrolimus and reduced clinical effect of tacrolimus, or an increase in blood concentrations of tacrolimus and risk of tacrolimus toxicity (see section 4.5).	Herbal preparations containing St. John's wort (Hypericum perforatum) or other herbal preparations should be avoided when taking Prograf due to the risk of interactions that lead to decrease in blood concentrations of tacrolimus and reduced clinical effect of tacrolimus (see section 4.5).	Special Warnings and Special Precautions for Use		
Weaker interactions have been observed with clotrimazole, clarithromycin, josamycin, nifedipine, nicardipine, diltiazem, verapamil, amiodarone, danazol, ethinylestradiol, omeprazole, nefazodone. and (Chinese) herbal remedies containing extracts of Schisandra sphenanthera.  In vitro the following substances have been shown to be potential inhibitors of tacrolimus metabolism: bromocriptine, cortisone, dapsone, ergotamine, gestodene, lidocaine, mephenytoin, miconazole, midazolam, nilvadipine, norethisterone, quinidine, tamoxifen, troleandomycin.  Grapefruit juice has been reported to increase the blood level of tacrolimus and should therefore be avoided.	Weaker interactions have been observed with clotrimazole, clarithromycin, josamycin, nifedipine, nicardipine, diltiazem, verapamil, amiodarone, danazol, ethinylestradiol, omeprazole, nefazodone.  In vitro the following substances have been shown to be potential inhibitors of tacrolimus metabolism: bromocriptine, cortisone, dapsone, ergotamine, gestodene, lidocaine, mephenytoin, miconazole, midazolam, nilvadipine, norethisterone, quinidine, tamoxifen, troleandomycin.  Grapefruit juice has been reported to increase the blood level of tacrolimus and should therefore be avoided.	Interaction with Other Medicaments and Other Forms of Interaction		
		Fertility, Pregnancy and Lactation		
		Preclinical Safety Data		
Metabolism and nutrition disorders very common: hyperglycaemic conditions,	Metabolism and nutrition disorders very common: hyperglycaemic	Adverse events		

diabetes mellitus, hyperkalaemia

common: hypomagnesaemia,

hypophosphataemia,

hypokalaemia, hypocalcaemia, hyponatraemia, fluid overload, hyperuricaemia, appetite decreased, anorexia, metabolic acidoses, hyperlipidaemia, hypercholesterolaemia, hypertriglyceridaemia, other electrolyte abnormalities

uncommon: dehydration, hypoproteinaemia,

hyperphosphataemia, hypoglycaemia common:

mellitus, hyperkalaemia hypomagnesaemia, hypophosphataemia, hypokalaemia, hypocalcaemia,

conditions, diabetes

hyponatraemia, fluid overload, hyperuricaemia, appetite decreased, anorexia, metabolic

acidoses,

hyperlipidaemia, hypercholesterolaemia, hypertriglyceridaemia, other electrolyte

abnormalities dehydration,

uncommon: dehydration,

hypoproteinaemia, hyperphosphataemia, hypoglycaemia

Cardiac disorders

common: ischaemic coronary artery

disorders, tachycardia

uncommon: ventricular arrhythmias and cardiac arrest, heart failures.

cardiac arrest, heart failures, cardiomyopathies, ventricular hypertrophy, supraventricular arrhythmias palpitations, ECG investigations abnormal, heart rate and pulse investigations

<del>abnormal</del>

rare: pericardial effusion

very rare: echocardiogram abnormal,

electrocardiogram OT

<mark>prolonged</mark>, Torsades de Pointes.

Cardiac disorders

common: ischaemic coronary artery

disorders, tachycardia

uncommon: ventricular arrhythmias

and cardiac arrest, heart

failures,

cardiomyopathies, ventricular hypertrophy,

supraventricular

arrhythmias palpitations, ECG investigations abnormal, heart-rate and pulse investigations

abnormal

rare: pericardial effusion

very rare: echocardiogram

abnormal,

electrocardiogram QT prolonged, *Torsades de* 

Pointes.

Gastrointestinal disorders

very common: diarrhoea, nausea

common: gastrointestinal inflammatory

conditions, gastrointestinal ulceration and perforation, gastrointestinal haemorrhages, stomatitis and ulceration,

ascites, vomiting,

gastrointestinal and abdominal pains, dyspeptic signs and symptoms, constipation, flatulence, bloating and distension, loose stools, gastrointestinal signs and

symptoms

uncommon: ileus paralytic, peritonitis, acute

and chronic pancreatitis, blood

amylase increased,

gastrooesophageal reflux disease, impaired gastric

Gastrointestinal disorders

very common: diarrhoea, nausea common: gastrointestinal

inflammatory conditions, gastrointestinal ulceration

and perforation, gastrointestinal

haemorrhages, stomatitis and ulceration, ascites, vomiting, gastrointestinal and abdominal pains, dyspeptic signs and symptoms, constipation, flatulence, bloating and distension, loose stools, gastrointestinal signs and

symptoms

uncommon: ileus paralytic, peritonitis,

acute and chronic

pancreatitis, blood emptying subileus, pancreatic pseudocyst amylase increased, rare: gastrooesophageal reflux disease, impaired gastric emptying subileus, pancreatic rare: pseudocyst Hepatobiliary disorders Hepatobiliary disorders common: hepatic enzymes and function common: hepatic enzymes and abnormalities, cholestasis and function abnormalities, jaundice, hepatocellular damage cholestasis and jaundice, and hepatitis, cholangitis hepatocellular damage rare: hepatitic artery thrombosis, and hepatitis, cholangitis

venoocclusive liver disease hepatitic artery rare:

very rare:

common:

common:

uncommon:

rare:

uncommon:

rare: motility decreased

General disorders and administration site

disorders, oedema, pain and discomfort, blood alkaline

multi-organ failure, influenza

perception disturbed

like illness, temperature

abnormal, blood lactate

weight decreased

fat tissue increased

dehydrogenase increased,

thirst, fall, chest tightness,

mobility decreased, ulcer

intolerance, chest pressure

stenosis

hepatic failure, bile duct thrombosis,

venoocclusive liver

disease

very rare: hepatic failure, bile duct

> stenosis abnormalities, cholestasis and jaundice, hepatocellular damage and hepatitis, cholangitis

hepatitic artery rare:

thrombosis.

venoocclusive liver

disease

very rare: hepatic failure, bile duct

stenosis

Musculoskeletal and connective tissue disorders Musculoskeletal and connective tissue arthralgia, muscle spasms, disorders

cramps, pain in limb, back pain common: arthralgia, muscle,

joint disorders cramps, pain in limb,

back pain

joint disorders uncommon:

conditions conditions

> asthenic conditions, asthenic conditions, febrile common:

> > febrile disorders, oedema, pain and discomfort,

General disorders and administration site

phosphatase increased, weight blood alkaline increased, body temperature

phosphatase increased, weight increased, body temperature perception

disturbed

multi-organ failure, uncommon: sensation, feeling jittery, feeling

influenza like illness, temperature intolerance, chest pressure sensation, feeling jittery, feeling abnormal, blood lactate

dehydrogenase increased, weight decreased

thirst, fall, chest rare:

> decreased, ulcer fat tissue increased

very rare: tightness, mobility <u>Investigations</u> common: hepatic enzymes and function abnormalities, blood alkaline very rare: phosphatase increased, weight

		T	
	ıncreased		
uncommon:	amylase increased, ECG		
	investigations abnormal, heart		
	rate and pulse investigations		
	abnormal, weight decreased,		
	blood lactate dehydrogenase		
	increased		
very rare:	echocardiogram abnormal,		
	electrocardiogram QT		
	prolonged		

## הודעה על החמרה (מידע בטיחות) בעלון לצרכן (מעודכן 3102.50)

\_\_\_July 13, 2015 \_\_\_\_ תאריך

שם תכשיר באנגלית ומספר הרישום

PROGRAF CAPSULES 0.5 mg, 1 mg, 5 mg

0.5 mg: 122 07 30215 00, 122 07 30215 11,

1 mg: 107 69 29158 00, 107 69 29158 11,

5 mg: 107 70 29159 00, 107 70 29159 11

Salomon, Levin & Elstein Ltd, POBox 3696, Petach-Tikva 49133 שם בעל הרישום

טופס זה מיועד לפרוט ההחמרות בלבד!

ההחמרות המבוקשות				
טקסט חדש	טקסט נוכחי	פרק בעלון		
		תוויות	าก	
		תי אין להשתמש תכשיר?		
		זהרות מיוחדות נוגעות לשימוש תרופה:	הו	
		ין להשתמש תרופה מבלי זיוועץ ברופא לפני תחלת הטיפול:	בר לו	
תרופות צמחיות המכילות את צמח ההיפריקום (St.Johns' Wort) או תמציות של צמח Schisandra תמציות של צמח sphenanthera הרפואה הסינית המסורתית).	צמח ההיפריקום (St.Johns' Wort)	נוכות בין • רופותיות:	תו	
וו פאודווס בית וובטורוביון.		ריון והנקה:	הו	
		צד תשתמש זרופה:	בר	
		ופעות לוואי:	רנו	